Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration

Radiology

Volumn 265, Issue 1, 2012, Pages 248-253

  Yang, Lucie ^a   Krefting, Ira ^a   Gorovets, Alex ^a   Marzella, Louis ^a   Kaiser, James ^a   Boucher, Robert ^a   Rieves, Dwaine ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; ECHOVIST; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIDOL; GADOVERSETAMIDE;

DRUG CLASSIFICATION; DRUG INFORMATION; DRUG LABELING; DRUG LEGISLATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY;

CONTRAST MEDIA; DRUG LABELING; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84866634595     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12112783     Document Type: Short Survey

References (11)

1. Information on gadolinium-based contrast agents. Food and Drug Administration Web site. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm142882.htm. Accessed March 11, 2012.
2. Prince MR, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging 1996;6(1):162-166. (Pubitemid 126702459)
3. Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011;65(6):1095-1106, e7.
4. 2009 Meeting Materials, Cardiovascular and Renal Drugs Advisory Committee, December 8, 2009. Food and Drug Administration Web site. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/ucm125999.htm. Accessed March 11, 2012.
5. Food and Drug Administration. Labeling for prescription drugs used in man. Fed Regist 1975;40:15392-15399. Accessed March 11, 2012.
6. U.S. Code of Federal Regulations. 21 CFR 201.57(c)(6). Food and Drug Administration Web site. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cfcfr/CFRSearch.cfm. Accessed March 11, 2012.
7. Guidance for industry and review staff: labeling for human prescription drug and biological products - determining established pharmacologic class for use in the highlights of prescribing information 2009. Food and Drug Administration Web site. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM186607.pdf. Accessed March 11, 2012.
8. Kanal E, Broome DR, Martin DR, Thomsen HS. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update. Radiology 2008;246(1):11-14.
9. Martin DR. Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD? Am J Kidney Dis 2010;56(3):427-430.
10. Pickering TG. Class effects and labeling of antihypertensive drugs. J Clin Hypertens (Greenwich) 2006;8(3):215-220.
11. Food and Drug Administration. Labeling and prescription drug advertising: content and format for labelling for human prescription drugs. Fed Regist 1979;44:37434-37467. Accessed March 11, 2012.